A study of Coversin in the treatment of atypical hemolytic uremic syndrome (aHUS)
Phase of Trial: Phase II
Latest Information Update: 06 Feb 2018
At a glance
- Drugs Coversin (Primary)
- Indications Haemolytic uraemic syndrome
- Focus Adverse reactions; Therapeutic Use
- 06 Feb 2018 Status changed from planning to recruiting, according to an Akari Therapeutics media release.
- 27 Apr 2017 New trial record
- 24 Apr 2017 According to an Akari Therapeutics media release, the company expects to initiate this trial in the second quarter of 2017, and anticipates data in the second quarter of 2018.